Sarah Lussier Hoskyn earned her Master’s degree in Economics at the University of Waterloo and a Bachelor degree in Economics at McGill University. She has 15 years of experience in pharmaceutical policy research in such areas as Canada’s regulatory and reimbursement performance, private drug plan drug costs trends, pricing policy (PMPRB), the value of R&D investments and clinical trials. From 2015 to 2020, Sarah was Director of Research, and Senior Analyst Regulatory Affairs and Market Access, Innovative Medicines Canada. From 2006 to 2015, Sarah was Engagement Manager, Senior Price Regulation Consultant, and Health Economist Consultant at Brogan Inc. (aka. IMS Brogan, IMS Health, Quintiles IMS, and IQVIA).

Sarah co-authored 2 papers on pharmaceutical policy topics that were published in the peer-reviewed journal Frontiers in Pharmacology. Sarah’s current focus is to help employers figure out their chronic disease burden in their workplace, diagnose the underlying causes, and find innovative evidence-based solutions to complement their existing benefits and wellness plans to improve their workplace health and productivity, and ultimately to reduce costs. This translates into a research interest in policies for health and wellness benefits that reduce the disease burden and resulting health care costs, and improve overall labour productivity and economic competitiveness.